{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-RDPMWM6U/5d92c314-7feb-4c02-bb30-1528bc2343ee/HTML","dcterms:extent":"26 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-RDPMWM6U/94699ea7-0dde-4c93-89b4-344f45ce49aa/PDF","dcterms:extent":"450 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-RDPMWM6U/17d38a35-2f85-4937-b28c-6265b17cc751/TEXT","dcterms:extent":"24 KB"}],"edm:TimeSpan":{"@rdf:about":"1929-2026","edm:begin":{"@xml:lang":"en","#text":"1929"},"edm:end":{"@xml:lang":"en","#text":"2026"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-RDPMWM6U","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/urn:nbn:si:spr-a30mfzkp"},{"@xml:lang":"sl","#text":"Zdravniški vestnik"}],"dcterms:issued":"2012","dc:creator":"Fürst, Jurij","dc:format":[{"@xml:lang":"sl","#text":"številka:6"},{"@xml:lang":"sl","#text":"letnik:81"},{"@xml:lang":"sl","#text":"str. 487-492"}],"dc:identifier":["ISSN:1318-0347","COBISSID:36099589","URN:URN:NBN:SI:doc-RDPMWM6U"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko zdravniško društvo"},"dc:subject":[{"@xml:lang":"en","#text":"drug"},{"@xml:lang":"sl","#text":"farmakologija"},{"@xml:lang":"sl","#text":"možgansko-žilne bolezni"},{"@xml:lang":"sl","#text":"preprečevanje"},{"@xml:lang":"sl","#text":"srčno-žilne bolezni"},{"@xml:lang":"sl","#text":"strategije"},{"@xml:lang":"sl","#text":"zdravila"}],"dcterms:temporal":{"@rdf:resource":"1929-2026"},"dc:title":{"@xml:lang":"sl","#text":"Preprečevanje bolezni z zdravili - prihranek ali strošek?| Prevention of diseases with drugs - savings or costs?|"},"dc:description":[{"@xml:lang":"sl","#text":"The paper discusses three approaches to cardiovascular disease prevention from the economic point of view: national programs for risk reduction, antiplatelet therapy and strategies of lipid lowering therapy. The most cost effective approach for cardiovascular risk reduction is a combination of population-wide prevention and the high-risk program with population screening. The high-risk program without populationwide prevention aggravates socio-economic inequalities. Acetylsalicylic acid is the antiplatelet drug of choice for cardiovascular disease prevention. Alternative antiplatelet drugs are cost-effective only for secondary prevention; clopidogrel only in case of contraindications for acetylsalicylic acid and dipyridamole in combination with acetylsalicylic acid only in the first two years after a cerebrovascular event. The \"treat-to-target\" model of lipid lowering treatment is less cost effective than an alternative approach to treating the whole population at risk with fixed doses of statins"},{"@xml:lang":"sl","#text":"Prispevek obravnava tri področja preprečevanja srčno-žilnih bolezni z ekonomskega vidika: nacionalne programe za zmanjševanje dejavnikov tveganja, antiagregacijska zdravila in strategije zdravljenja lipidov. Stroškovno najučinkovitejši pristop za zmanjšanje dejavnikov tveganja za srčno-žilne bolezni združuje populacijski program v kombinaciji s presejalnim. Izvajanje samo presejalnega programa je stroškovno manj učinkovito in vodi v večje razslojevanje družbe. Acetilsalicilna kislina je antiagregacijsko zdravilo izbire za preprečevanje aterosklerotičnih zapletov. Alternativna antiagregacijska zdravila so stroškovno učinkovita le v okviru sekundarne preventive klopidogrel za preprečevanje srčno-žilnih dogodkov, kadar je uporaba acetilsalicilne kisline kontraindicirana in kombinacija dipiridamola z acetilsalicilno kislino za preprečevanje ponovnih možgansko-žilnih zapletov prvi dve leti po prvem dogodku. Strategija zdravljenja lipidov v ciljne vrednosti ima verjetno slabšo stroškovno učinkovitost kot alternativna strategija zdravljenja vse populacije z določeno ravnjo tveganja za srčno-žilne bolezni z enotnimi odmerki statinov"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-RDPMWM6U","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-RDPMWM6U"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-RDPMWM6U/94699ea7-0dde-4c93-89b4-344f45ce49aa/PDF"},"edm:rights":{"@rdf:resource":"http://creativecommons.org/licenses/by-nc/4.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko zdravniško društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-RDPMWM6U/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-RDPMWM6U"}}}}